Skip to content

TriangleGet started

← Full study record

NCT03141177 · OUTCOME

Number of Participants With Laboratory Values Grade Shifting From Baseline

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · Source last updated 2026-08-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From first dose to 30 days following last dose (Up to 30 Months)

What was measured

Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.

Analysis population: All Treated Participants

Groups in this outcome

Treatment A

Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment B

Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment C

Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment A	320
Treatment B	50
Treatment C	320

Reported measurements

Hemoglobin: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	251

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	117	Not reported	Not reported	Not reported	Not reported
Treatment B	23	Not reported	Not reported	Not reported	Not reported
Treatment C	190	Not reported	Not reported	Not reported	Not reported

Hemoglobin: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	251

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	8	Not reported	Not reported	Not reported	Not reported
Treatment B	5	Not reported	Not reported	Not reported	Not reported
Treatment C	15	Not reported	Not reported	Not reported	Not reported

Platelet Count: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	129	Not reported	Not reported	Not reported	Not reported
Treatment B	24	Not reported	Not reported	Not reported	Not reported
Treatment C	216	Not reported	Not reported	Not reported	Not reported

Platelet Count: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	2	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	30	Not reported	Not reported	Not reported	Not reported

Leukocytes: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	116	Not reported	Not reported	Not reported	Not reported
Treatment B	26	Not reported	Not reported	Not reported	Not reported
Treatment C	206	Not reported	Not reported	Not reported	Not reported

Leukocytes: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	1	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	16	Not reported	Not reported	Not reported	Not reported

Lymphocytes: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	228
Treatment B	36
Treatment C	225

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	95	Not reported	Not reported	Not reported	Not reported
Treatment B	20	Not reported	Not reported	Not reported	Not reported
Treatment C	102	Not reported	Not reported	Not reported	Not reported

Lymphocytes: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	228
Treatment B	36
Treatment C	225

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	15	Not reported	Not reported	Not reported	Not reported
Treatment B	4	Not reported	Not reported	Not reported	Not reported
Treatment C	23	Not reported	Not reported	Not reported	Not reported

Neutrophil: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	112	Not reported	Not reported	Not reported	Not reported
Treatment B	22	Not reported	Not reported	Not reported	Not reported
Treatment C	209	Not reported	Not reported	Not reported	Not reported

Neutrophil: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	10	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	36	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	131	Not reported	Not reported	Not reported	Not reported
Treatment B	31	Not reported	Not reported	Not reported	Not reported
Treatment C	115	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	9	Not reported	Not reported	Not reported	Not reported
Treatment B	6	Not reported	Not reported	Not reported	Not reported
Treatment C	5	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase (AST): Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	245	Not reported	Not reported	Not reported	Not reported
Treatment B	42	Not reported	Not reported	Not reported	Not reported
Treatment C	177	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase (AST): Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	25	Not reported	Not reported	Not reported	Not reported
Treatment B	19	Not reported	Not reported	Not reported	Not reported
Treatment C	8	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase (ALT): Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	249	Not reported	Not reported	Not reported	Not reported
Treatment B	43	Not reported	Not reported	Not reported	Not reported
Treatment C	121	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase (ALT) Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	31	Not reported	Not reported	Not reported	Not reported
Treatment B	24	Not reported	Not reported	Not reported	Not reported
Treatment C	11	Not reported	Not reported	Not reported	Not reported

Bilirubin: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	55	Not reported	Not reported	Not reported	Not reported
Treatment B	17	Not reported	Not reported	Not reported	Not reported
Treatment C	68	Not reported	Not reported	Not reported	Not reported

Bilirubin: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	3	Not reported	Not reported	Not reported	Not reported
Treatment B	3	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Creatinine: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	123	Not reported	Not reported	Not reported	Not reported
Treatment B	22	Not reported	Not reported	Not reported	Not reported
Treatment C	132	Not reported	Not reported	Not reported	Not reported

Creatinine: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	4	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	2	Not reported	Not reported	Not reported	Not reported

Amylase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	285
Treatment B	46
Treatment C	277

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	117	Not reported	Not reported	Not reported	Not reported
Treatment B	26	Not reported	Not reported	Not reported	Not reported
Treatment C	77	Not reported	Not reported	Not reported	Not reported

Amylase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	285
Treatment B	46
Treatment C	277

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	28	Not reported	Not reported	Not reported	Not reported
Treatment B	10	Not reported	Not reported	Not reported	Not reported
Treatment C	16	Not reported	Not reported	Not reported	Not reported

Lipase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	47
Treatment C	300

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	127	Not reported	Not reported	Not reported	Not reported
Treatment B	27	Not reported	Not reported	Not reported	Not reported
Treatment C	114	Not reported	Not reported	Not reported	Not reported

Lipase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	47
Treatment C	300

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	42	Not reported	Not reported	Not reported	Not reported
Treatment B	20	Not reported	Not reported	Not reported	Not reported
Treatment C	40	Not reported	Not reported	Not reported	Not reported

Hypernatremia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	33	Not reported	Not reported	Not reported	Not reported
Treatment B	7	Not reported	Not reported	Not reported	Not reported
Treatment C	24	Not reported	Not reported	Not reported	Not reported

Hypernatremia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hyponatremia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	136	Not reported	Not reported	Not reported	Not reported
Treatment B	30	Not reported	Not reported	Not reported	Not reported
Treatment C	111	Not reported	Not reported	Not reported	Not reported

Hyponatremia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	34	Not reported	Not reported	Not reported	Not reported
Treatment B	8	Not reported	Not reported	Not reported	Not reported
Treatment C	37	Not reported	Not reported	Not reported	Not reported

Hyperkalemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	111	Not reported	Not reported	Not reported	Not reported
Treatment B	25	Not reported	Not reported	Not reported	Not reported
Treatment C	82	Not reported	Not reported	Not reported	Not reported

Hyperkalemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	15	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Hypokalemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	61	Not reported	Not reported	Not reported	Not reported
Treatment B	8	Not reported	Not reported	Not reported	Not reported
Treatment C	35	Not reported	Not reported	Not reported	Not reported

Hypokalemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	10	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	5	Not reported	Not reported	Not reported	Not reported

Hypercalcemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	314
Treatment B	48
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	30	Not reported	Not reported	Not reported	Not reported
Treatment B	7	Not reported	Not reported	Not reported	Not reported
Treatment C	46	Not reported	Not reported	Not reported	Not reported

Hypercalcemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	314
Treatment B	48
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	1	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Hypocalcemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	314
Treatment B	48
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	170	Not reported	Not reported	Not reported	Not reported
Treatment B	25	Not reported	Not reported	Not reported	Not reported
Treatment C	73	Not reported	Not reported	Not reported	Not reported

Hypocalcemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	314
Treatment B	48
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	6	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	2	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	304

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	38	Not reported	Not reported	Not reported	Not reported
Treatment B	9	Not reported	Not reported	Not reported	Not reported
Treatment C	26	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	304

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	12	Not reported	Not reported	Not reported	Not reported
Treatment B	4	Not reported	Not reported	Not reported	Not reported
Treatment C	7	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	304

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	146	Not reported	Not reported	Not reported	Not reported
Treatment B	16	Not reported	Not reported	Not reported	Not reported
Treatment C	77	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	304

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	4	Not reported	Not reported	Not reported	Not reported
Treatment B	1	Not reported	Not reported	Not reported	Not reported
Treatment C	1	Not reported	Not reported	Not reported	Not reported

Hyperphosphatemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	307
Treatment B	49
Treatment C	307

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hyperphosphatemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	307
Treatment B	49
Treatment C	307

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hypophosphatemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	307
Treatment B	49
Treatment C	307

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	211	Not reported	Not reported	Not reported	Not reported
Treatment B	33	Not reported	Not reported	Not reported	Not reported
Treatment C	147	Not reported	Not reported	Not reported	Not reported

Hypophosphatemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	307
Treatment B	49
Treatment C	307

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	85	Not reported	Not reported	Not reported	Not reported
Treatment B	12	Not reported	Not reported	Not reported	Not reported
Treatment C	31	Not reported	Not reported	Not reported	Not reported

Hyperglycemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	170
Treatment B	33
Treatment C	173

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	74	Not reported	Not reported	Not reported	Not reported
Treatment B	17	Not reported	Not reported	Not reported	Not reported
Treatment C	76	Not reported	Not reported	Not reported	Not reported

Hyperglycemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	170
Treatment B	33
Treatment C	173

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	6	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Hypoglycemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	262
Treatment B	45
Treatment C	270

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	67	Not reported	Not reported	Not reported	Not reported
Treatment B	9	Not reported	Not reported	Not reported	Not reported
Treatment C	37	Not reported	Not reported	Not reported	Not reported

Hypoglycemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	262
Treatment B	45
Treatment C	270

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	2	Not reported	Not reported	Not reported	Not reported
Treatment B	1	Not reported	Not reported	Not reported	Not reported
Treatment C	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
117
group Id
OG001
value
23
group Id
OG002
value
190
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
251
units
Participants
title
Hemoglobin: Any grade
categories
measurements
group Id
OG000
value
8
group Id
OG001
value
5
group Id
OG002
value
15
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
251
units
Participants
title
Hemoglobin: Grade 3-4
categories
measurements
group Id
OG000
value
129
group Id
OG001
value
24
group Id
OG002
value
216
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
48
group Id
OG002
value
310
units
Participants
title
Platelet Count: Any grade
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
group Id
OG002
value
30
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
48
group Id
OG002
value
310
units
Participants
title
Platelet Count: Grade 3-4
categories
measurements
group Id
OG000
value
116
group Id
OG001
value
26
group Id
OG002
value
206
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Leukocytes: Any grade
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
16
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Leukocytes: Grade 3-4
categories
measurements
group Id
OG000
value
95
group Id
OG001
value
20
group Id
OG002
value
102
denoms
counts
group Id
OG000
value
228
group Id
OG001
value
36
group Id
OG002
value
225
units
Participants
title
Lymphocytes: Any grade
categories
measurements
group Id
OG000
value
15
group Id
OG001
value
4
group Id
OG002
value
23
denoms
counts
group Id
OG000
value
228
group Id
OG001
value
36
group Id
OG002
value
225
units
Participants
title
Lymphocytes: Grade 3-4
categories
measurements
group Id
OG000
value
112
group Id
OG001
value
22
group Id
OG002
value
209
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Neutrophil: Any grade
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
2
group Id
OG002
value
36
denoms
counts
group Id
OG000
value
316
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Neutrophil: Grade 3-4
categories
measurements
group Id
OG000
value
131
group Id
OG001
value
31
group Id
OG002
value
115
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
310
units
Participants
title
Alkaline Phosphatase: Any grade
categories
measurements
group Id
OG000
value
9
group Id
OG001
value
6
group Id
OG002
value
5
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
310
units
Participants
title
Alkaline Phosphatase: Grade 3-4

denoms

counts
group Id
OG000
value
320
group Id
OG001
value
50
group Id
OG002
value
320
units
Participants

description

Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.

groups

description
Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
id
OG000
title
Treatment A
description
Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
id
OG001
title
Treatment B
description
Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle
id
OG002
title
Treatment C

param Type

COUNT_OF_PARTICIPANTS

population Description

All Treated Participants

reporting Status

POSTED

time Frame

From first dose to 30 days following last dose (Up to 30 Months)

title

Number of Participants With Laboratory Values Grade Shifting From Baseline

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice